Alchemab Therapeutics signs landmark $415m licensing agreement for ATLX-1282 with Eli Lilly and Company
– New agreement with Lilly to license ATLX-1282, a first-in-class IND-ready programme for neurodegenerative conditions targeting a novel receptor and mechanism
– Deal worth up to $415m including upfront and downstream, plus royalties on top
– ATLX-1282 is the first programme out of Alchemab’s entirely novel platform which generates and analyses millions of antibody sequences from resilient individuals
– Builds on existing discovery collaboration agreement with Lilly announced in January 2025 to discover, develop and commercialise up to five novel therapeutic candidates for ALS
Cambridge, UK, 6 May 2025 – Alchemab Therapeutics (Alchemab), the next generation biopharmaceutical company which uses the power of human immune evolution to identify and develop naturally occurring therapeutic antibodies from resilient individuals, today announces that it has entered into a licensing agreement with Eli Lilly and Company (Lilly) for ATLX-1282, Alchemab’s first-in-class IND-ready programme for amyotrophic lateral sclerosis (ALS) and other neurodegenerative conditions.
